The stock price of Clearside Biomedical Inc (NASDAQ: CLSD) has jumped by 14.78 compared to previous close of 1.15. Despite this, the company has seen a gain of 10.92% in its stock price over the last five trading days. globenewswire.com reported 2024-10-09 that – Maintained Stable Visual Acuity and Anatomical Control Over 9 Months – – Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events – – 67% of CLS-AX Participants Did Not Require Any Additional Treatment up to 6 Months – – Reduced Treatment Burden by 84% Over 6 Months – – Webcast and Conference Call Today at 8:00 A.M. ET with Management and Key Opinion Leader and Board-Certified Retinal Specialist, Roger Goldberg, M.D.
Is It Worth Investing in Clearside Biomedical Inc (NASDAQ: CLSD) Right Now?
CLSD has 36-month beta value of 2.30. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLSD is 63.26M, and currently, short sellers hold a 0.41% ratio of that float. The average trading volume of CLSD on October 22, 2024 was 667.85K shares.
CLSD’s Market Performance
CLSD’s stock has seen a 10.92% increase for the week, with a 0.76% rise in the past month and a 14.78% gain in the past quarter. The volatility ratio for the week is 8.41%, and the volatility levels for the past 30 days are at 11.86% for Clearside Biomedical Inc The simple moving average for the past 20 days is 4.49% for CLSD’s stock, with a 2.80% simple moving average for the past 200 days.
Analysts’ Opinion of CLSD
Many brokerage firms have already submitted their reports for CLSD stocks, with Chardan Capital Markets repeating the rating for CLSD by listing it as a “Buy.” The predicted price for CLSD in the upcoming period, according to Chardan Capital Markets is $6 based on the research report published on August 21, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CLSD reach a price target of $5. The rating they have provided for CLSD stocks is “Outperform” according to the report published on June 25th, 2024.
Wedbush gave a rating of “Outperform” to CLSD, setting the target price at $9 in the report published on December 15th of the previous year.
CLSD Trading at 13.35% from the 50-Day Moving Average
After a stumble in the market that brought CLSD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.74% of loss for the given period.
Volatility was left at 11.86%, however, over the last 30 days, the volatility rate increased by 8.41%, as shares surge +10.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.10% upper at present.
During the last 5 trading sessions, CLSD rose by +10.92%, which changed the moving average for the period of 200-days by -10.81% in comparison to the 20-day moving average, which settled at $1.2632. In addition, Clearside Biomedical Inc saw 12.82% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLSD starting from Chong Ngai Hang Victor, who purchase 23,500 shares at the price of $1.06 back on Jun 24 ’24. After this action, Chong Ngai Hang Victor now owns 63,500 shares of Clearside Biomedical Inc, valued at $24,910 using the latest closing price.
YERXA BENJAMIN R, the Director of Clearside Biomedical Inc, purchase 7,813 shares at $1.31 during a trade that took place back on May 15 ’24, which means that YERXA BENJAMIN R is holding 17,957 shares at $10,235 based on the most recent closing price.
Stock Fundamentals for CLSD
Current profitability levels for the company are sitting at:
- -3.42 for the present operating margin
- 0.97 for the gross margin
The net margin for Clearside Biomedical Inc stands at -4.45. The total capital return value is set at -0.92. Equity return is now at value -1310.02, with -91.51 for asset returns.
Based on Clearside Biomedical Inc (CLSD), the company’s capital structure generated 2.5 points at debt to capital in total, while cash flow to debt ratio is standing at -0.41. The debt to equity ratio resting at -1.67. The interest coverage ratio of the stock is -5.86.
Currently, EBITDA for the company is -24.78 million with net debt to EBITDA at -1.14. When we switch over and look at the enterprise to sales, we see a ratio of 17.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.07.
Conclusion
To put it simply, Clearside Biomedical Inc (CLSD) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
